Back to Search Start Over

Multi-institutional review of sinonasal and skull base chondrosarcoma: 20-year experience.

Authors :
Eide JG
Kshirsagar RS
Harris JC
Civantos A
Brody RM
Lee JYK
Alonso-Basanta M
Lazor JW
Nabavizadeh A
Wang BY
Kuan EC
Palmer JN
Adappa ND
Source :
Head & neck [Head Neck] 2022 Dec; Vol. 44 (12), pp. 2686-2695. Date of Electronic Publication: 2022 Sep 02.
Publication Year :
2022

Abstract

Background: Chondrosarcomas of the sinonasal cavity and skull base are uncommon malignancies. We sought to provide long-term outcomes at two tertiary care centers.<br />Methods: Patients with chondrosarcoma treated between 2000 and 2021 were included. The primary outcomes were overall survival (OS) and disease-specific survival (DSS).<br />Results: Thirty-eight patients met inclusion criteria. Fourteen patients had sinonasal (36.8%), 7 petroclival (18.4%), and 17 other primary skull base lesions (44.7%). Twenty-eight patients (73.7%) underwent radiation with an average dose of 67.3 ± 15.1 Gy. Eighteen patients (47.4%) required revision surgery for recurrence. 1, 5, and 10-year OS were 97.3%, 93.1%, and 74.7%. DSS at 5- and 10-year survival was 95.7%. Adjuvant radiation was associated with improved OS (HR: 0.12; 95% CI: 0.02-0.75, p = 0.023).<br />Conclusion: We present our experience over the last 20 years treating chondrosarcomas. Favorable survival outcomes can be achieved but recurrence requiring repeat resection is common.<br /> (© 2022 Wiley Periodicals LLC.)

Details

Language :
English
ISSN :
1097-0347
Volume :
44
Issue :
12
Database :
MEDLINE
Journal :
Head & neck
Publication Type :
Academic Journal
Accession number :
36052545
Full Text :
https://doi.org/10.1002/hed.27178